TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) patients who harbor anaplastic lymphoma kinase (ALK) rearrangement are sensitive to an ALK inhibitor (crizotinib), but not all ALK-positive patients benefit equally from crizotinib treatment. We analyze the impact of TP53 mutations on response...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thorac Dis
Autores principales: Wang, Wen-Xian, Xu, Chun-Wei, Chen, Yan-Ping, Liu, Wei, Zhong, Li-Hua, Chen, Fang-Fang, Zhuang, Wu, Huang, Yun-Jian, Huang, Zhang-Zhou, Chen, Rong-Rong, Guan, Yan-Fang, Yi, Xin, Lv, Tang-Feng, Zhu, Wei-Feng, Lu, Jian-Ping, Wang, Xiao-Jiang, Shi, Yi, Lin, Xian-Dong, Chen, Gang, Song, Yong
Formato: Artigo
Lenguaje:Inglês
Publicado: AME Publishing Company 2018
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6006073/
https://ncbi.nlm.nih.gov/pubmed/29997966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.04.98
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares